HIV PrEP Faces Psychological, Financial Obstacles

New York Times: Are We Ready for HIV’s Sexual Revolution?
Donald McNeil, science and health reporter for the New York Times

“The FDA has taken a drug — Truvada — that was approved for HIV treatment in 2004, and approved it for prevention, a use called pre-exposure prophylaxis, or PrEP. On May 14, the Centers for Disease Control and Prevention endorsed PrEP, saying it could benefit up to 500,000 Americans. … Widespread use of the drugs could fight [HIV infections] — but two imposing obstacles loom. … The first is psychological. … The second is financial…” (5/23).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.